Defunct Company
Total Trials
4
As Lead Sponsor
1
As Collaborator
3
Total Enrollment
62
NCT02088398
Alternative 10 mg/mL Liquid Formulation of ACY 1215 (Ricolinostat) in Healthy Subjects
Phase: Phase 1
Role: Lead Sponsor
Start: Mar 31, 2014
Completion: Apr 30, 2014
NCT02091063
ACY-1215 for Relapsed/Refractory Lymphoid Malignancies
Phase: Phase 1/2
Role: Collaborator
Start: Apr 2, 2014
Completion: May 5, 2019
NCT02632071
ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer
Start: Mar 1, 2016
Completion: Sep 30, 2020
NCT02787369
ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
Start: May 31, 2016
Completion: Apr 30, 2027